DewDiligence
3 years ago
NKTR’s Bempeg fails as addend to Opdivo in first-line melanoma:
https://finance.yahoo.com/news/bristol-myers-squibb-nektar-announce-105900961.html Bristol Myers Squibb and Nektar Therapeutics today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR). The DMC notified the companies that the third primary endpoint of overall survival (OS) did not meet statistical significance at the first interim analysis.
Given there was no additional clinical benefit in the doublet therapy arm compared to the monotherapy arm for the primary endpoints of PFS and ORR, and based on the data reviewed by the DMC, the companies have decided to unblind the trial and to perform no additional analyses for the OS endpoint.
Additionally, based on the results from PIVOT IO-001, the companies have also made the decision to discontinue enrollment and unblind the ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma.
DewDiligence
4 years ago
NKTR +18% on clinical-trial_collaboration_testing Bempeg+Keytruda in_H&N_cancer:
https://finance.yahoo.com/news/nektar-announces-agreement-phase-2-130000352.html
NKTR is receiving no cash from MRK—only free drug for use in the trial. Rather, unding for the trial is being provided by NKTR’s financing deal with SJC Pharma (https://finance.yahoo.com/news/nektar-announces-collaboration-sfj-pharmaceuticals-125900283.html ).
Note that the 3-year PD-(L)1 exclusivity period of the BMY/NKTR collaboration, which was announced on 2/14/18, has now expired, enabling NKTR to test Bempeg with any PD-(L)1 agent of its choosing.
p.s. Even after today’s pop, NKTR’s share price is down about 70% from the day of the BMY announcement three years ago.
czni
5 years ago
Hey gang,
Im a quiet holder but have a question driving me crazy!
The MU wait for chips was so Ridiculous even after having this giant to do in Las Vegas.
Do you know the people that paid all around the world to go to Las Vegas just to hear that ticker symbol was not given out at that meeting?
You had to purchase his book in order to get it.
As soon as I dug it up,
I gave it out to everybody.
Now this big Pharma company whoever they are,
are getting ready to purchase 11% of a biotech company.
It has not happened yet but I’m looking for the ticker symbol for the biotech company.
The Pharma company is already out of reach but the biotech company There’s a couple of very important patents making the merger happen quicker.
Does anybody know the biotech company ticker symbol?
I need something that’s going to climb and keep climbing.
On a sidenote,
before my wife finds out I lost just about everything on the stock that should have gone to 50 plus wish i had known they had trouble with their CEO and the CFO having private meetings putting the company under investigation and stopping all Trading for over a month. It trades for 1/10000 of a penny now. I put everything on it!!!
. If you can throw that out to me, you could possibly change my marriage LOL.
Thanks very much and good skill to everyone!
The only job that I have ever had that did not look forward to the weekends!!! Happy hunting!
I dont have pm but please use it if you can. Happy Holidays!
Thanks gang
Sweet Virginia Breeze